ホーム › PubMed Lab 🤖 自分の AI で使う ⭐ 保存した論文

🔬 PubMed Lab

日本語で入力するだけで、PubMed の英語論文を検索できるリサーチアシスタントです。
卒論・研究テーマ探し、興味のある論文を効率よく見つけられます。

「2型糖尿病の発症に関わる5つの要因とメカニズム」の検索結果

170,540 件中 10 件を表示 (5084 ms) · ⭐ 保存した論文

AI が生成した英語クエリを見る
("Diabetes Mellitus, Type 2"[MeSH] OR "type 2 diabetes"[tiab]) AND (etiology[sh] OR pathogenesis OR mechanism OR "risk factors"[MeSH] OR pathophysiology)

💡 2型糖尿病の発症要因とメカニズムを網羅的に検索。病因論、病態生理、リスク因子のサブヘディングを活用

🎓 卒論・修論テーマを AI が提案

この 5 本の論文を俯瞰して、あなたが実際に卒論・修論で研究できるテーマを 3 つ提案します。

残り 3 / 3 回 (今日)

📖 このサイトの解説記事から (日本語で読める)

PubMed Trivia が過去に取り上げた論文を日本語で解説している記事です。

🔍 PubMed の検索結果

  • Polycystic ovarian syndrome.

    Subbulaxmi Trikudanathan · The Medical clinics of North America · 2015

    Women with PCOS present with signs of chronic anovulation, hyperandrogenism, and metabolic abnormalities. The NIH recently embraced the Rotterdam criteria to broadly identify all the phenotypes of PCOS. Women with PCOS are often obese with insulin resistance and hence have an increased susceptibility to glucose intolerance and type 2 diabetes. Future research should focus on the genetic, epigeneti…

    📄 PubMed で読む (PMID: 25456652)
  • Metformin and sleep health in older adults with type 2 diabetes: Mechanisms, clinical evidence, and future directions, a narrative review.

    Vijaya Paul Samuel, Suresh Kumar Srinivasamurthy, Naveen Kumar Naryana 他 · Primary care diabetes · 2026

    Sleep disturbances affect up to half of older adults with type 2 diabetes mellitus (T2DM) and represent a clinically meaningful but under addressed dimension of diabetes care. Metformin, the universally recommended first-line agent for T2DM, exerts multiple pleiotropic effects, including modulation of AMPK signaling, circadian clock gene expression, neuroinflammation, and neuropathic pain, that ar…

    📄 PubMed で読む (PMID: 42527195)
  • Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.

    Michael H Davidson · Postgraduate medicine · 2014

    Cardiovascular (CV) disease remains the major cause of mortality and morbidity in patients with type 2 diabetes mellitus (T2DM). The pathogenesis of CV disease in T2DM is complex and multifactorial, and includes abnormalities in endothelial cells, vascular smooth muscle cells, myocardium, platelets, and the coagulation cascade. Dipeptidyl peptidase-4 (DPP-4) inhibitors are a newer class of agents …

    📄 PubMed で読む (PMID: 24918792)
  • Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential.

    S S Torekov, S Madsbad, J J Holst 他 · Obesity reviews : an official journal of the International Association for the Study of Obesity · 2011

    Obesity is common and associated with a high rate of morbidity and mortality; therefore, treatment is of great interest. At present, bariatric surgery is the only truly successful treatment of severe obesity. Mimicking one of the effects of bariatric surgery, namely the increased secretion of glucagon-like peptide (GLP)-1, by artificially increasing the levels of GLP-1 might prove successful as ob…

    📄 PubMed で読む (PMID: 21401851)
  • Polycystic ovary syndrome and insulin resistance: A focus on pathogenesis, risk factors, and therapeutic strategies.

    Jyoti Singla, Shubhi Yadav, Jiaur R Gayen 他 · Journal of reproductive immunology · 2026

    Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder characterized by significant reproductive and metabolic complications. Insulin resistance (IR) plays a central role in the pathophysiology of PCOS and contributes to several associated metabolic abnormalities. This review highlights the key mechanisms underlying PCOS, including IR, hyperandrogenism, cardiovascular disease, gut microbi…

    📄 PubMed で読む (PMID: 42531755)
  • [Metabolically obese with normal weight individuals: an intriguing phenotype].

    E Beck, A J Scheen · Revue medicale de Liege · 2009

    Obesity, especially abdominal obesity, is the main risk factor of metabolic syndrome. However, there are obviously non obese individuals who are metabolically abnormal and therefore exposed to an increased risk of cardiovascular complications. Unfortunately, those persons fail to be detected because of a falsely reassuring body weight. The present paper aims at better understanding the etiopathoge…

    📄 PubMed で読む (PMID: 19317097)
  • Multiple risk factor intervention in type 2 diabetes: an opportunity not to be missed.

    J R Cockcroft, I B Wilkinson, H Yki-Järvinen 他 · Diabetes, obesity & metabolism · 2001

    📄 PubMed で読む (PMID: 11213594)
  • What are the cardiovascular effects of the newer classes of drugs for type 2 diabetes?

    Jean Covino, Jennifer Hoffman · JAAPA : official journal of the American Academy of Physician Assistants · 2018

    New classes of drugs to treat type 2 diabetes are continually being developed and marketed. The FDA has issued guidance to the pharmaceutical industry that newer hypoglycemic agents should not be associated with unacceptable increases in cardiovascular risk. To date, five trials have assessed specific cardiovascular endpoints for these newer agents. Empagliflozin and liraglutide have been found to…

    📄 PubMed で読む (PMID: 29470367)
  • [Treat insulin resistance and look out for mental stress. New strategies in the prevention of type 2 diabetes].

    Andreas F H Pfeiffer · MMW Fortschritte der Medizin · 2005

    📄 PubMed で読む (PMID: 15903055)
  • [Should we prescribe regular physical activity for patients presenting with type 2 diabetes?].

    J F Gautier · Diabete & metabolisme · 1994

    📄 PubMed で読む (PMID: 7859899)